Close
Tineco's 180° Innovation: The New FLOOR ONE Stretch S6 with HyperStretch Technology Jun 3, 2024 03:15AM

MILAN--(BUSINESS WIRE)-- Tineco updates its ecosystem with a new model: the FLOOR ONE Stretch S6. This floor washer has a unique peculiarity: it is able to bend 180° degrees, so as to reach any surface, whether under furniture or a hidden corner of the house.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240603868347/en/

TINECO FLOOR ONE Stretch S6 (Photo: Business Wire)

Equipped with the latest... (continue reading...)


Mursla Bio Presents Breakthrough Liquid Biopsy Technology for Extracellular Vesicles in Cell Press Jun 3, 2024 03:03AM

Novel and scalable analysis of extracellular vesicles sub-types detailed in Cell Press’ iScience

CAMBRIDGE, England--(BUSINESS WIRE)-- Mursla Bio is pleased to announce the publication of its latest peer-reviewed paper in iScience, an interdisciplinary journal of the esteemed Cell Press. The paper showcases Mursla Bio’s breakthrough technology for the analysis of extracellular vesicles (EV) sub-types within biofluids such as blood. EVs are important actors in... (continue reading...)


Aqara Launches Amazon Brand Store in the Netherlands to Broaden Smart Home Accessibility Jun 3, 2024 03:00AM

NEW YORK--(BUSINESS WIRE)-- Aqara, a global leader and pioneer in IoT, announced the debut of its Amazon brand store in the Netherlands. This expansion to the Amazon marketplace marks a significant step in increasing the accessibility of Aqara's smart home lineup to Dutch consumers.

Since opening its first European Amazon brand store in the UK in 2021, Aqara has consistently broadened its reach in the e-commerce marketplace in this region, now including France,... (continue reading...)


EDF Teams with Accenture and Kraken Technologies to Accelerate Customer Transformation Jun 3, 2024 02:59AM

Initiative supported by a broader Accenture and Kraken ecosystem partnership focused on helping utilities transform customer experience

LONDON--(BUSINESS WIRE)-- Accenture (NYSE: ACN) and Kraken Technologies are helping EDF’s UK retail business accelerate the migration of customers to its new platform, enabling them to effectively manage their energy use and cost.

EDF has migrated over five million meter points in the UK onto Kraken, the technology behind... (continue reading...)


Invicara launches digitaltwin-factory at Digital Construction Week Jun 3, 2024 02:58AM

DUBLIN--(BUSINESS WIRE)-- Invicara will unveil digitaltwin-factory, an open-source program, at the Digital Construction Week in ExCeL London, 5th & 6th June. Enterprise innovation teams, and software solution providers can now join the digitaltwin-factory community, access free to use open source digital twin building blocks, and create their own commercial applications.

Invicara’s decision to embrace open-source software, is aimed at accelerating innovation,... (continue reading...)


More Business Wire

View Older Stories

Jun 3, 2024 02:37AM Veolia Launches a New Employee Stock Ownership Plan Offered to nearly 190,000 Group employees
Jun 3, 2024 02:30AM Nidec Announces the Status of Own Share Repurchase
Jun 3, 2024 02:15AM Wedding Season Is Open: A Radiant Bride and a Wedding to Remember with Quanta's Laser Skincare!
Jun 3, 2024 02:00AM Ferguson Files Form 8-K
Jun 3, 2024 02:00AM Modern Card Issuing Platforms to Issue 35% of All Payment Cards by 2029, as Banks Begin to Compete on User Experience
Jun 3, 2024 02:00AM AM Best to Host Insurance Market Briefing in Amsterdam to Review Challenges and Emerging Issues Facing European Carriers
Jun 3, 2024 02:00AM Igloo Coolers Makes Its First-Ever Debut in the Active Cooling Category at Outdoor by ISPO
Jun 3, 2024 02:00AM Thermo Fisher Scientific Opens New GMP-certified Ultra-cold Facility in the EU to Accelerate Advanced Therapies Development
Jun 3, 2024 02:00AM Discover® Global Network Study Shows 85% of Consumers are Less Likely to Interact with a Business Due to a Poor Payment Experience
Jun 3, 2024 02:00AM Medincell’s Partner Teva presented New Data Providing Schizophrenia Treatment Insights into Switching to UZEDY® (risperidone) from Invega Sustenna® (paliperidone palmitate)
Jun 3, 2024 02:00AM Germans Trias i Pujol Hospital in Spain Launches Telehealth and Remote Patient Management Program Using Masimo W1® Medical Watches and Radius VSM™ Wearable Continuous Vital Signs Monitors
Jun 3, 2024 02:00AM Axway Announces the Signing of Binding Agreements for the Acquisition of Sopra Banking Software
Jun 3, 2024 02:00AM Sopra Steria: A Significant Milestone Achieved in the Group’s Strategy to Refocus Its Activities on Digital Services and Solutions
Jun 3, 2024 01:47AM “MOURI Tech” Expands Global Footprint with Acquisition of “Versant Systems”, Strengthening Presence in APAC Region
Jun 3, 2024 01:30AM GenSight Biologics Appoints William Monteith to its Board of Directors
Jun 3, 2024 01:00AM Avanzanite Bioscience Reports AKANTIOR® Received Positive CHMP Opinion and Announces Corporate Expansion Into 26 European Countries
Jun 3, 2024 12:01AM Triumph Motorcycle Dealers Ranked First in Industry Study for Providing Quick and Easy Service Appointments
Jun 2, 2024 10:51PM Appointment of Director to Woodside Board
Jun 2, 2024 09:00PM Nissan Demonstrates Autonomous-Drive Mobility Services Progress on Public Roads
Jun 2, 2024 08:35PM WEBTOON Entertainment Announces Public Filing of Registration Statement for Proposed Initial Public Offering
Jun 2, 2024 07:00PM Other World Computing Introduces Intel Thunderbolt Share for the Thunderbolt Go Dock
Jun 2, 2024 06:00PM New Blood Test Predicts Recurrence of Breast Cancer, Months or Even Years Before Relapse
Jun 2, 2024 02:32PM TAGRISSO® (osimertinib) reduced the risk of disease progression or death by 84% in patients with unresectable, Stage III EGFR-mutated lung cancer vs. placebo in LAURA Phase III trial
Jun 2, 2024 12:30PM CatalYm Reports Impressive and Lasting Responses Including Multiple Complete Responses in Heavily Pretreated, Late- to Last-Line Metastatic NSCLC, Urothelial and Hepatocellular Cancer Patients Treated
Jun 2, 2024 10:56AM Belantamab Mafodotin combination reduced the risk of disease progression or death by nearly 50% versus standard of care combination in relapsed/refractory multiple myeloma
Jun 2, 2024 10:01AM Puma Biotechnology Announces Presentation of Findings from a Phase II Study of Alisertib in Endocrine-Resistant Metastatic Breast Cancer (TBCRC 041)
Jun 2, 2024 09:30AM Tempus Introduces New HER2 & FOLR1 Testing Solutions to Support Personalized Patient Care
Jun 2, 2024 09:00AM ZT Systems Announces ACX200 Solutions Featuring NVIDIA GB200 Grace Blackwell Superchips for Next-Generation Accelerated Computing
Jun 2, 2024 08:30AM Denodo Opens ME Regional Head Office in Kingdom of Saudi Arabia to Meet Growing Demand for Data Management and AI
Jun 2, 2024 08:30AM Denodo Integrates NVIDIA NIM Inference Microservices to Accelerate and Optimize AI Capabilities for Enterprises
Jun 2, 2024 08:05AM IMFINZI® (durvalumab) is the first and only immunotherapy to show survival benefit in limited-stage small cell lung cancer in global Phase III trial, reducing the risk of death by 27% vs. placebo
Jun 2, 2024 08:00AM Gilead and Arcus Announce Etrumadenant Plus Zimberelimab Regimen Significantly Reduced the Risk of Death in Third-line Metastatic Colorectal Cancer
Jun 2, 2024 08:00AM Massive Bio and Mika Health Combine AI and Next-Generation Sequencing Biomarker Testing to Empower Cancer Patients On Treatment and Those Searching for and Participating in Clinical Trials in the Unit
Jun 2, 2024 08:00AM ENHERTU® (fam-trastuzumab deruxtecan-nxki) demonstrated a median progression-free survival of 13.2 months in HR-positive, HER2-low and HER2-ultralow metastatic breast cancer following one or more lin
Jun 2, 2024 08:00AM ENHERTU® Demonstrated a Median Progression-Free Survival of 13.2 Months in HR Positive, HER2 Low and HER2 Ultralow Metastatic Breast Cancer Following One or More Lines of Endocrine Therapy
Jun 2, 2024 07:00AM June Joy at Juicy Stakes Casino
Jun 1, 2024 02:25PM New Data Provide Schizophrenia Treatment Insights into Switching to UZEDY® (risperidone) Extended-Release Injectable Suspension from Invega Sustenna® (paliperidone palmitate)
Jun 1, 2024 02:20PM Teva Presents First Real-World Data from the IMPACT-TD Registry Study at Psych Congress Elevate 2024
Jun 1, 2024 10:00AM "Experience the Luxury of Japanese Tradition and Cuisine" Reservations for the New Inbound Experience Tour in Osaka's Tondabayashi Begin on June 1, 2024!
Jun 1, 2024 10:00AM First Ascent Biomedical Presents Findings from Clinical Studies in Pediatric and Adult Cancers Using its AI-Enhanced Functional Precision Medicine Platform at ASCO 2024
Jun 1, 2024 09:30AM Tempus Announces Expansion of Collaboration with AstraZeneca to Leverage Tempus Next to Support Guideline-directed Biomarker Testing in NSCLC
Jun 1, 2024 09:15AM Postmedia Announces Closing of Previously Announced Transaction with the Klein Group
Jun 1, 2024 09:00AM Sally Hansen® and GLAAD Reprise Their Partnership for the 6th Year With a Launch That Celebrates the LGBTQ+ Community
Jun 1, 2024 09:00AM Ankyra Therapeutics Announces Trial in Progress Poster Presentation at 2024 ASCO Meeting and Approval of ANK-101 Phase 1 Protocol Amendment
Jun 1, 2024 08:10AM Nuvation Bio Announces Data from Pivotal Phase 2 TRUST-I Study of its Investigational ROS1 Inhibitor, Taletrectinib, are Published in the Journal of Clinical Oncology and Reported at 2024 ASCO Annual
Jun 1, 2024 08:00AM Accutar Biotechnology Presents Phase 1 Data of AC699 Monotherapy in Patients with ER+ / HER2- Breast Cancer at ASCO 2024
Jun 1, 2024 08:00AM Massive Bio to Unveil Drug Utilization Optimizer (DUO) at ASCO Annual Meeting 2024
Jun 1, 2024 08:00AM KRAZATI (adagrasib) Demonstrated Statistically Significant Improvement in Progression-Free Survival in Patients with Pretreated Locally Advanced or Metastatic KRASG12C-Mutated Non-Small Cell Lung Canc
Jun 1, 2024 08:00AM Pfizer’s ADCETRIS® Regimen Produces Clinically Meaningful Improvement in Overall Survival in Patients with Relapsed/​Refractory Diffuse Large B-cell Lymphoma (DLBCL)
Jun 1, 2024 08:00AM Takeda and Pfizer Announce Four-Year Results from Positive Phase 3 HD21 Trial of Additional ADCETRIS® (brentuximab vedotin) Combination in Frontline Hodgkin Lymphoma
View Older Stories